Agreement for Large-Scale Genotyping Studies
News Sep 23, 2005
Illumina, Inc. has announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK).
Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium™ assays to conduct genetic studies for thousands of samples provided by GSK.
The blanket agreement enables multiple projects to be conducted over period of time.
Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies.
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.